Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

Loss of Deubiquitylase USP2 Triggers Development of Glioblastoma Via TGF-β Signaling.

Identification of Ubiquitin-Specific Protease 32 As an Oncogene in Glioblastoma and the Underlying Mechanisms

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination

Ubiquitin-specific protease 4 promotes glioblastoma multiforme via activating ERK pathway

Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis

USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1

USP9X deubiquitinates TRRAP to promote glioblastoma cell proliferation and migration and M2 macrophage polarization

Deubiquitinase USP9X Deubiquitinates Β-Catenin and Promotes High Grade Glioma Cell Growth

Ubiquitin-specific Protease 22 Acts As an Oncoprotein to Maintain Glioma Malignancy Through Deubiquitinating B Cell-Specific Moloney Murine Leukemia Virus Integration Site 1 for Stabilization.

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

Deubiquitinase PSMD14 promotes tumorigenicity of glioblastoma by deubiquitinating and stabilizing β‐catenin

USP10 deubiquitinates RUNX1 and promotes proneural-to-mesenchymal transition in glioblastoma

Suppression of the USP10/CCND1 Axis Induces Glioblastoma Cell Apoptosis

Deubiquitinating enzyme USP48 mediates pyroptosis and meliorates immune evasion in tumors by stabilizing GSDME expression

Ubiquitin-specific Protease 2a Stabilizes MDM4 and Facilitates the P53-Mediated Intrinsic Apoptotic Pathway in Glioblastoma.

Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

USP7 Inhibition Induces Apoptosis in Glioblastoma by Stabilizing ARF4

UBE2S facilitates glioblastoma progression through activation of the NF-κB pathway via attenuating K11-linked ubiquitination of AKIP1

USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression

USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization